Cover Image

癌症的個體化醫療:醫生層級主要的促進要素、課題的評估 (EU5個國家)

Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)

出版商 FirstWord 商品編碼 334906
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
癌症的個體化醫療:醫生層級主要的促進要素、課題的評估 (EU5個國家) Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)
出版日期: 2015年05月01日 內容資訊: 英文

本報告以對EU5個國家(法國、德國、西班牙、義大利及英國) 150名癌症專門醫生的調查結果為基礎,提供 癌症專門醫生考慮的個體化醫療領域中的重要問題,課題及機會相關考察,癌症專門醫生將來打算引進何種個體化醫療的調查。


  • EU5個國家的醫生對於認識的個體化醫療利用價值如何排名?
  • EU5個國家的醫生對於個體化醫療對醫生、患者來說的主要潛在優點如何排名?
  • 對於含固態腫瘤、血液腫瘤的所有癌症類型的治療來說,個體化醫療目前利用相關之EU5個國家的醫生的考察為何?
  • EU5個國家的醫生對於存取資料的課題如何排名?
  • 如果存取資料的課題在最小限度的情況下,EU5個國家的醫生要指示個體化醫療到哪個程度?
  • EU5個國家的醫生認為什麼重要的要素使現在、未來的個體化醫療利用成為可能?


  • EU5個國家的癌症專門醫生的個體化醫療的認識相關考察,對患者照護的影響,及個體化醫療的整體臨床結果的價值
  • 個體化醫療的重要優點相關見解,個體化醫療獲取創新治療方法的相關主要問題
  • 未來個體化醫療的利用相關意見,及有降低引進率可能性的主要障礙
Product Code: 596200462

Gain exclusive insights on the perceived value and benefits of personalised medicine and on the key challenges and opportunities in relation to implementation from treating oncologists.

Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5) is based on survey results from 150 oncologists (104 medical oncologists and 46 haematologist-oncologists) in France, Germany, Spain, Italy and the UKand offers insights on what oncologists believe are the critical issues, challenges and opportunities within the personalised medicines space, and how oncologists intend to adopt personalised medicine in the future.

Quantitative Analysis

A great deal of anticipation and expectation surrounds personalised medicine. While there have been some notable successes, the promise of personalised medicine - right medicine, right patient, right time - has failed to materialise in many disease areas where a personalised approach could drive better patient outcomes. Concerns amongst key stakeholder groups remain, particularly in relation to development, access and implementation of personalised healthcare strategies.

This survey provides EU5 physician insights into personalised medicine within the oncology setting. By understanding what oncologists in the major markets in Europe think about the key challenges, opportunities and concerns, companies operating in the oncology market and seeking to leverage personalised medicine for their products can gain a deep understanding of what's needed to drive long-term commercial success.

Gain Answers to Key Questions

  • How do EU5 physicians rank perceived application values of personalised medicine?
  • How do EU5 physicians rank the top potential benefits of personalised medicine for physicians and patients?
  • What are EU5 physician insights on the current usage of personalised medicine for the treatment of all cancer types, including solid and blood tumours?
  • How do EU5 physicians rank access and data challenges?
  • If access and data challenges were minimal - what proportion of EU5 physicians would prescribe personalised medicines?
  • What critical factors do EU5 physicians think enable effective current and future usage of personalised medicine?

Report Features

Filled with charts and up-to-the-minute survey analysis, this report offers:

  • Precise and timely analysis of EU5 oncologist awareness, perception of value, promise and benefits of personalised medicine
  • Data and insight on current usage and access status, and challenges related to personalised medicine access and adoption intention
  • EU5 Oncologist views on the critical enablers and success factors of personalised medicine, as well as anticipated future developments

Top Takeaways

  • Insight on EU5 oncologist awareness of personalised medicine, their impact on patient care and the value of personalised medicines overall clinical outcomes
  • Views on the critical benefits of personalised medicine, and key issues related to how personalised medicine can support access to innovative therapies
  • Opinions on the future use of personalised medicine, and what key barriers are likely to slow adoption rates
Back to Top